Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Cancinoma (NPC)
Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy
The goal of this phase I clinical trial is to evaluate the safety and feasibility of a multimodal evaluation-guided surveillance-intervention strategy in patients with newly diagnosed N3 nasopharyngeal carcinoma.
- Trial name
- NCT07636499
- Testing
- Multimodal Evaluation-Guided Surveillance-Intervention Strategy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiquan Zhu
Dysphagia
Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06265844
- Testing
- Intermittent Oral-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Zeng Changhao
Nasopharyngeal Carcinoma
LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) which has either come back, not gone away or is at high risk for coming back after the best treatment we know for this disease.
- Trial name
- NATELLA (NCT00516087)
- Testing
- Genetically modified CTLs
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Neoplasms
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
The purpose of this study is to compare individualized clinical target volume (CTV) based on disease extension risk atlas and computer-aided delineation with traditional CTV in intensity modulated radiotherapy (IMRT) for…
- Trial name
- NCT02627807
- Testing
- IMRT using individualized CTV, IMRT using traditional CTV, Gemcitabine and cisplatin (induction chemotherapy)
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Adult
A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
This study will assess the safety and tolerability and pharmacokinetics of BH009 in patients with advanced head and neck squamous (non-nasopharyngeal) and ovarian cancer.
- Trial name
- NCT06232863
- Testing
- BH009
- Where
- 5 sites in China
- Volunteers
- 24 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Nasopharyngeal Carcinoma
Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients
Nasopharyngeal carcinoma (NPC) is one of the most common maligancies of China. In the era of intensity-modulated radiotherapy (IMRT), the 5-year overall survival (OS) has now reached 85.0% or more.
- Trial name
- NCT03290820
- Testing
- Radiotherapy, Concurrent chemotherapy, Aspirin
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma by AJCC V8 Stage
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
A Randomized, Double-Blind, Multi-Center Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) + Serplulimab (HLX10, Recombinant Anti-PD-1 Humanized…
- Trial name
- NCT05513573
- Testing
- HLX07, HLX10, chemotherapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Henlius Biotech
Nasopharyngeal Carcinoma, Radiation Therapy Complication
Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
Patients with head and neck cancer who underwent irradiation have a higher risk of developing severe carotid stenosis, and eventually develop to transient ischemic attack or stroke.
- Trial name
- NCT02022293
- Testing
- Atorvastatin
- Where
- 6 sites in China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Cancer
Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00629226
- Testing
- cetuximab, bortezomib, cisplatin
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Xerostomia, Mouth Dryness
Acupuncture for Prevention of Radiation-Induced Xerostomia
The goal of this clinical research study is to learn if acupuncture is effective in preventing xerostomia (dry mouth) in cancer patients who receive radiation treatment to the head and neck area.
- Conditions
- Xerostomia, Mouth Dryness, Nasopharyngeal Cancer
- Trial name
- NCT00430378
- Testing
- Acupuncture, Standard Care
- Where
- China
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT05020925
- Testing
- SHR-1701, Famitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with carboplatin followed by chemoradiation in treating patients with recurrent head and neck…
- Conditions
- Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT01847326
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis
oral administration of Tegio capsules for 12 months for NPC patients with high risk of metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant metastasis，safety was also evaluated.
- Trial name
- NCT03904225
- Testing
- Tegafur-Gimeracil-Oteracil
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, Image-Guided Biopsy
Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images
Due to the occult anatomic location of the nasopharynx and frequent presence of adenoid hyperplasia, the positive rate for nasopharyngeal carcinoma identification during biopsy is low, thus leading to delayed or missed diagnosis…
- Trial name
- NCT05202626
- Testing
- Nasopharyngeal Endoscopy image-guided Biopsy
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Sciences
Nasopharyngeal Carcinoma
GNT Induction Treatment in Locally Advanced NPC
The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal…
- Trial name
- NCT06026878
- Testing
- gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Air Force Military Medical University, China
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
- Trial name
- NCT07650266
- Testing
- Cemiplimab, Fianlimab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nasopharyngeal Carcinoma (NPC)
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to…
- Trial name
- NCT06839066
- Testing
- HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
- Where
- 15 sites in China
- Volunteers
- 70 people
- Sponsor
- Shanghai Henlius Biotech
Nasopharyngeal Carcinoma
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction…
- Trial name
- NCT04456322
- Testing
- RT plus Nimotuzumab, RT plus Cisplatin
- Where
- China
- Volunteers
- 381 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03932266
- Testing
- Endostar, Cisplatin, Docetaxel
- Volunteers
- 73 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Oral Mucositis
Streptococcus Salivarius K12@Lip@GSH Alleviates Oral Mucositis in Patients Undergoing Radiotherapy
Radiation-induced oral mucositis (RIOM) is the most common oral complication of cancer patients receiving radiotherapy and/or chemotherapy, leading to poor quality of life.
- Trial name
- NCT06446180
- Testing
- SsK12@Lip@GSH
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The General Hospital of Western Theater Command
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.